Profile cover photo
Profile photo
BioTime
121 followers -
Developing stem cell-based therapies and products in the area of regenerative medicine
Developing stem cell-based therapies and products in the area of regenerative medicine

121 followers
About
BioTime's posts

Post has attachment
Public
Read GEN's coverage of the opening of our new cGMP cell therapy manufacturing center in Israel.



Post has attachment
Public
BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel

> Supplying OpRegen® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration

> Center has Capability to Manufacture Additional BioTime Products-

#RegenMed
$BTX

Post has attachment
Public
Watch BioTime Co-CEO Dr. Michael D. West deliver the Plenary Presentation at the World Stem Cell Summit on Thursday, December 8, 2016:

The Future of Human Aging: Implications of Induced Tissue Regeneration (iTR)

$BTX
#RegMed

http://bit.ly/2hnuI7i

Post has attachment
Public


BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit

> Presentation Will Describe the Future of Aging Research and iTRTM, an Emerging Area of Research from BioTime

> Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to Extend the Healthy Lifespan”

#RegMed
$BTX

Post has attachment
Public
Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting

> 3D-imaging Suggests Grafts Retained Volume Over the Assessment Period

> Cells Remained Viable and Proliferated in Renevia Hydrogel

> Longer-term data continues to be collected

$BTX

http://bit.ly/2foAFwh


Post has attachment
Public
BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016

- Will Also Present at Young Jewish Professionals Life Sciences & Pharmaceuticals CEO Symposium-


Post has attachment
Public
BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development

> Brings Wealth of Value Creation Experience to BioTime




Post has attachment
Public
BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine

> New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide

Post has attachment
Public
BioTime to report Second Quarter Results on Tuesday, August 9, 2016. $BTX

Post has attachment
Wait while more posts are being loaded